Related Experiment Video
Updated: May 20, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Unlocking new frontiers in AKR1B10 inhibition and future opportunities
Sanzida Yeasrim1, Hafiz Tanveer Ahmad2, Mengxiao Chen1
1School of Pharmacy, China Pharmaceutical University, Nanjing, 211198, People's Republic of China.
Abstract:
Numerous illnesses, including cancer, inflammation, and metabolic disorders, have been linked to the enzyme aldo-keto reductase family 1 member B10 (AKR1B10). The pathogenic consequences of AKR1B10, its structural and functional characteristics, and the rationale behind concentrating on it during drug discovery are examined in this review. The classification, structure-activity relationships, and computational design of AKR1B10 inhibitors are discussed, along with the current status of their studies. The challenges of developing inhibitors, such as selectivity, resistance mechanisms, and pharmacokinetics, are also analyzed. Finally, we examine prospective insights and advancements for the future, including combination treatments, novel chemical scaffolds, and the expansion of therapeutic applications outside cancer.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Inhibition of CDK Activity
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
